Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review
IntroductionAdvanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas are characterized by an aggressive course and a very poor prognosis. Due to the limited benefit of immunotherapy in patients with HER2-negative tumors, new therapeutic targets are sought. Zolbetuximab is a chimeric mo...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2026-07-01
|
| סדרה: | Frontiers in Immunology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1870010/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|